We are making
early stage cancer

100,000x

easier to find

Early-stage cancer is notoriously difficult and expensive to find.

But it doesn’t have to be.

Using nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – we have developed an approach that is showing tremendous promise in finding stage I cancer, when it is most treatable.

Our initial focus is on early detection of difficult-to-treat cancers, such as ovarian and lung, which today are often found too late to save lives.

Our Approach

Our Approach

The Mercy Halo test is the first and only test for early cancer detection based on analysis of single extracellular vesicles (EVs), shed into the blood at a rate of 1,000 per cell per day and precisely traceable to their tissue of origin.

Learn more

EVs FOR EARLY DETECTION

Recognizing the power of extracellular vesicles in early cancer detection is a recent phenomenon. But there is growing support for this unassuming microenvironment.

Learn more

our approach
About Mercy

ABOUT MERCY

Our remarkable team runs the gamut from our young MD/PhD candidate co-founder with scientific imagination and no limits, to our seasoned advisors who have founded two of the most successful early cancer detection companies in history.

Learn more

Our Approach

Our Approach

The Mercy Halo test is the first and only test for early cancer detection based on analysis of single extracellular vesicles (EVs), shed into the blood at a rate of 1,000 per cell per day and precisely traceable to their tissue of origin.

Learn more

About Mercy

EVs FOR EARLY DETECTION

Recognizing the power of extracellular vesicles in early cancer detection is a recent phenomenon. But there is growing support for this unassuming microenvironment.

Learn more

About Mercy

ABOUT MERCY

Our remarkable team runs the gamut from our young MD/PhD candidate co-founder with scientific imagination and no limits, to our seasoned advisors who have founded two of the most successful early cancer detection companies in history.

Learn more

"The difference between the Mercy approach and nucleic acid-based approaches is the huge increase in the abundance of the potential signal. I believe this novel approach may well crack the early detection problem. To be clear, the company has not demonstrated superiority to date – but its R&D program has moved rapidly and its clinical program is sound."

Stanley Lapidus, Founder of Exact Sciences and Cytyc, Inventor of Cologuard and Thin Prep

 

Let’s Collaborate!

Please use the form below for questions or collaboration inquiries